Skip to content
Homepage
Author:
Eisai Inc.
Posted Date:
July 14, 2026
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Eisai Inc.
July 14, 2026
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Eisai Inc.
July 14, 2026
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
Eisai Inc.
July 13, 2026
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer’s Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer’s Association International Conference® (AAIC®) 2026
Eisai Inc.
July 13, 2026
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026
Eisai Inc.
July 12, 2026
Eisai to Showcase Alzheimer’s Disease Portfolio with More Than 50 Presentations at the Alzheimer’s Association International Conference® 2026 (AAIC®)
Eisai Inc.
June 29, 2026
Eisai and CaringKind Launch New Initiative to Address Mealtime and Nutrition Needs for People Living with Alzheimer’s Disease and Related Dementias
Eisai Inc.
June 1, 2026
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease
Eisai Inc.
May 8, 2026
Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer’s Disease at the 78th American Academy of Neurology’s Annual Meeting
Eisai Inc.
April 9, 2026
EISAI TO BEGIN ENROLLING PHASE 2 STUDY IN PATIENTS WITH NARCOLEPSY
Eisai Inc.
March 26, 2026
1
2
Next
